Drug intelligence / Profile preview

inactivated poliovirus vaccine (fractional dose) + bivalent oral polio vaccine

Development stage
Unknown
Lead developer
Sanofi
Modality
Recombinant Proteins and Enzymes, Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration
Intradermal, Oral
01

Overview

This is a combination immunization regimen using two types of poliovirus vaccines: - **Fractional Inactivated Poliovirus Vaccine (fIPV):** A reduced-dose (1/5th of the full dose) inactivated poliovirus vaccine administered intradermally. It induces immunity against all three types of polioviruses and is used to optimize limited IPV supply while maintaining high immunogenicity[8][7][1]. - **Bivalent Oral Polio Vaccine (bOPV):** An oral live attenuated vaccine that protects against poliovirus types 1 and 3 but not type 2[3][2]. The sequential schedule typically involves two doses of fIPV followed by two or three doses of bOPV during infancy. This approach provides robust protection against all wild-type polioviruses and supports global eradication efforts by maximizing immune response while conserving IPV supplies[1][3]. The mechanism of action for both components is induction of protective immunity via stimulation of humoral and mucosal immune responses.

Other names
fractional IPV + bOPVf-IPV + bOPVfractional-dose inactivated polio vaccine + bivalent oral polio vaccine
02

Targets

NeuraminidaseEukaryotic translation initiation factor 4 gamma 1 and Polypyrimidine tract-binding protein 1 interaction with Poliovirus Sabin Internal Ribosome Entry Site

Beyond the preview

Go deeper on inactivated poliovirus vaccine (fractional dose) + bivalent oral polio vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on inactivated poliovirus vaccine (fractional dose) + bivalent oral polio vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call